Blood Irradiator; Used To Prevent Rare But Serious Complication of Blood Transfusions
Blood irradiator is a life-saving technology that prevents
graft-versus-host disease associated with blood transfusions, a condition that
can be fatal for blood transfusion recipients with compromised immune systems.
Blood irradiation is a therapy in which blood components are irradiated prior
to transfusion, to prevent proliferation of certain types of T lymphocytes. It
is an alternative medical procedure in which the blood is exposed to low level
light (often laser light) for therapeutic reasons.
According to Coherent
Market insights the Blood
Irradiator Market Size, Share, Outlook, and Opportunity
Analysis, 2022-2028
These medical devices are extensively used in blood banks
and hospitals for blood irradiation and for clinical and research purposes,
such as in cancer research and for blood transfusion. Blood irradiation is
necessary for those who are at risk for graft versus host disease, including
individuals receiving platelets, patients undergoing hematopoietic
transplantation, and fetuses receiving intrauterine transfusions. Blood
irradiator is used to expose a wide range of samples to gamma radiation for a
variety of purposes.
Irradiation of blood & blood products by gamma rays is a
proven and safe method eliminate the risk of post transfusion graft versus host
disease Gamma Irradiation Chambers are also used extensively in academic
institutions for research and analysis. Irradiated blood is often used to prevent
a very rare but serious complication of blood transfusions called
'transfusion-associated graft-versus-host disease', in which lymphocytes from
transfused blood component attack the recipient's tissues, especially the skin,
bone marrow, and gastrointestinal tract.
Gamma irradiation of blood products has been the mainstay of
TA-GVHD prevention. Japan uses universal irradiation of all labile blood
components, as a higher rate of TA-GvHD has been reported due to common HLA
tissue types. The Japan Society of Transfusion Medicine and Cell Therapy issued
first guidelines on the irradiation of blood and blood components to prevent
PT-GVHD in 1992, and issued the fifth version of the guidelines in 2010.
Comments
Post a Comment